Cargando…

Immune checkpoint inhibitor in recurrent hypermutated glioblastoma with POLE mutation

Detalles Bibliográficos
Autores principales:	Sathornsumetee, Sith, Nunta-aree, Sarun, Cheunsuchon, Pornsuk
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2021
Materias:	Brief Communication
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8325752/ https://www.ncbi.nlm.nih.gov/pubmed/34345822 http://dx.doi.org/10.1093/noajnl/vdab093

Ejemplares similares

Detection of temozolomide-induced hypermutation and response to PD-1 checkpoint inhibitor in recurrent glioblastoma
por: Daniel, Paul, et al.
Publicado: (2022)

Recurrence of Hypophysitis After Immune Checkpoint Inhibitor Rechallenge
por: Park, Benjamin C, et al.
Publicado: (2022)

Molecular profiling and sequential somatic mutation shift in hypermutator tumours harbouring POLE mutations
por: Hatakeyama, Keiichi, et al.
Publicado: (2018)

High prevalence of unusual KRAS, NRAS, and BRAF mutations in POLE ‐ hypermutated colorectal cancers
por: Favre, Loetitia, et al.
Publicado: (2022)

Allergic fungal rhinosinusitis presented as a unilateral nasal mass: A first case report from Thailand and literature review
por: Lumyongsatien, Jate, et al.
Publicado: (2022)

Seronegative antibody‐mediated neurology after immune checkpoint inhibitors
por: Wilson, Robert, et al.
Publicado: (2018)

Immune checkpoint inhibitors in the onset of myasthenia gravis with hyperCKemia
por: Takamatsu, Koutaro, et al.
Publicado: (2018)

Germline POLE mutation in a child with hypermutated medulloblastoma and features of constitutional mismatch repair deficiency
por: Lindsay, Holly, et al.
Publicado: (2019)

Frequent POLE-driven hypermutation in ovarian endometrioid cancer revealed by mutational signatures in RNA sequencing
por: Davila, Jaime I., et al.
Publicado: (2021)

Risk of COVID‐19 in Patients with Cancer Receiving Immune Checkpoint Inhibitors
por: Klebanov, Nikolai, et al.
Publicado: (2021)

Clinicoserological insights into patients with immune checkpoint inhibitor‐induced myasthenia gravis
por: Masi, Gianvito, et al.
Publicado: (2023)

Heterogeneity of response to immune checkpoint blockade in hypermutated experimental gliomas
por: Aslan, Katrin, et al.
Publicado: (2020)

Rare cases of medulloblastoma with hypermutation
por: Bagchi, Aditi, et al.
Publicado: (2021)

EpCAM expression in squamous cell carcinoma of the uterine cervix detected by monoclonal antibody to the membrane-proximal part of EpCAM
por: Chantima, Warangkana, et al.
Publicado: (2017)

Incidence, Clinical Characteristics, and Predictors of Cardiovascular Immune-Related Adverse Events Associated with Immune Checkpoint Inhibitors
por: Isawa, Tsuyoshi, et al.
Publicado: (2022)

Pre-treatment serum albumin and mutational burden as biomarkers of response to immune checkpoint blockade
por: Yoo, Seong-Keun, et al.
Publicado: (2022)

Clinical and Molecular Characterization of POLE Mutations as Predictive Biomarkers of Response to Immune Checkpoint Inhibitors in Advanced Cancers
por: Garmezy, Benjamin, et al.
Publicado: (2022)

Consider Myocarditis When Patients Treated with Immune Checkpoint Inhibitors Present with Ocular Symptoms
por: Rhee, John Y, et al.
Publicado: (2022)

POLE/POLD1 mutation in non‐exonuclease domain matters for predicting efficacy of immune‐checkpoint‐inhibitor therapy
por: Chen, Yan‐Xing, et al.
Publicado: (2021)

A Cavernous Venous Malformation of the Orbit Mimicking an Idiopathic Orbital Inflammation
por: Chirapapaisan, Niphon, et al.
Publicado: (2020)

Diabetes insipidus and panhypopituitarism as a first presentation of silent adenocarcinoma of lung: a case report and literature review
por: Sirinvaravong, Sirinart, et al.
Publicado: (2019)

Immune Checkpoint Inhibitors for the Therapy of Thymoma
por: Quilez, Alicia, et al.
Publicado: (2020)

PBRM1 mutation and preliminary response to immune checkpoint blockade treatment in non-small cell lung cancer
por: Zhou, Huaqiang, et al.
Publicado: (2020)

Checkpoint kinase 1 negatively regulates somatic hypermutation
por: Frankenberger, Samantha, et al.
Publicado: (2014)

Association between immune checkpoint inhibitors and myocardial infarction in Asians: A population‐based self‐controlled case series
por: Chan, Jeffrey Shi Kai, et al.
Publicado: (2023)

Immune Checkpoint Inhibition as Single Therapy for Synchronous Cancers Exhibiting Hypermutation: An IRRDC Study
por: Henderson, Jacob J., et al.
Publicado: (2022)

Germline RAD54L with somatic POLE defect implicated in Hypermutation phenotype: case report
por: Zohud, Bisan Abdalfatah, et al.
Publicado: (2020)

Hyperprogressive NSCLC With Two Immune-Checkpoint Inhibitors
por: Kasparian, Saro, et al.
Publicado: (2020)

Pathological complete response to immune checkpoint inhibitor in patients with colorectal cancer liver metastases harboring POLE exonuclease domain mutation
por: Wen, Lei, et al.
Publicado: (2022)

FRI178 The Clinicopathological Distinction And Malignant Potential In Patients With Lipid-rich and Lipid-poor Non-functioning Adrenal Adenoma
por: Pengkhum, Pornrumpa, et al.
Publicado: (2023)

Impact of Label Restriction on Checkpoint-Inhibitor Use in Bladder Cancer and Changes in Mortality
por: Vader, Daniel T, et al.
Publicado: (2022)

Melanoma-Specific Clinical Outcomes of Inpatient Immune Checkpoint Blockade Treatment
por: Loo, Kimberly, et al.
Publicado: (2022)

Immune checkpoint therapy in colorectal cancer: is first better than last?
por: Kaneko, Yui, et al.
Publicado: (2023)

Downregulation of KEAP1 in melanoma promotes resistance to immune checkpoint blockade
por: Fox, Douglas B., et al.
Publicado: (2023)

Recurrent targets of aberrant somatic hypermutation in lymphoma
por: Khodabakhshi, Alireza Hadj, et al.
Publicado: (2012)

Sparganosis Presenting as Cauda Equina Syndrome with Molecular Identification of the Parasite in Tissue Sections
por: Boonyasiri, Adhiratha, et al.
Publicado: (2013)

Immune-Active Microenvironment in Small Cell Carcinoma of the Ovary, Hypercalcemic Type: Rationale for Immune Checkpoint Blockade
por: Jelinic, Petar, et al.
Publicado: (2018)

Infections Simulating Immune Checkpoint Inhibitor Toxicities: Uncommon and Deceptive
por: Gudiol, Carlota, et al.
Publicado: (2022)

Collision of germline POLE and PMS2 variants in a young patient treated with immune checkpoint inhibitors
por: Berrino, Enrico, et al.
Publicado: (2022)

Constitutive reduction in the checkpoint inhibitor, CTLA-4, does not accelerate SLE in NZM 2328 mice
por: Stohl, William, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_qs7ii6fk7n3r6dhq70preoid0b